Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Morphotek, a subsidiary of Eisai, has signed a cooperative R&D agreement with the National Cancer Institute, or NCI, for the development of therapeutic antibodies to a cancer-associated protein identified by NCI researchers.
Subscribe to our email newsletter
Morphotek will apply its proprietary Morphodoma antibody technology for the development of novel therapeutic antibodies for use in the treatment of prostate cancer. The NCI will provide its expertise in evaluating the lead antibodies for therapeutic efficacy.
Philip Sass, executive vice president and COO of Morphotek, said: “This agreement is an important addition to our already existing collaborative relationship with NCI to develop novel therapies for the treatment of various cancer types. The NCI brings significant expertise in the evaluation and validation of lead antibodies to cancer-specific proprietary targets, which complements Morphotek’s expertise in the development of antibodies as potential cancer treatments through biological and immunological mechanisms.”